The treatment with THZ-P1-2 alone or combination therapy suppressed the expression of BCL2A1, another antiapoptotic member of the BCL2 family associated with venetoclax resistance in AML [39,40]. The gene discussed is BCL2; the disease is acute myeloid leukemia.